PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
07 mai 2024 08h30 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a...
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
07 mai 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
16 avr. 2024 16h30 HE
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
13 mars 2024 08h20 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
08 févr. 2024 15h30 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
Deep Brain Stimulation Devices Market to Witness USD 3.5 Billion Expansion by 2033, Driven by Surging Demand and Ongoing Research Advancements
11 janv. 2024 06h55 HE
|
Market.Us
New York, Jan. 11, 2024 (GLOBE NEWSWIRE) -- According to market.us, the Deep Brain Stimulation Devices Market is expected to reach around USD 3.5 Billion by 2033, indicating substantial growth...
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
17 nov. 2023 08h00 HE
|
PaxMedica, Inc.
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
Nerve Repair and Regeneration Market Size Worth USD 14.21 Billion in 2032 | Emergen Research
15 nov. 2023 12h55 HE
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Nerve Repair and Regeneration Market will be worth USD 14.21 Billion by 2032, according to a current analysis by Emergen Research. The growth...
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
31 oct. 2023 08h00 HE
|
PaxMedica, Inc.
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological...
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
13 oct. 2023 09h30 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...